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Sexual development in humans is only partly understood at the molecular level. It is dependent on genetic control
primarily induced by the sex chromosomal differences between males and females. This leads to the development
of the gonads, whereby afterwards the differentiation of the apparent phenotype is controlled by hormone action.
Sex steroids may exert permanent and temporary effects. Their organizational features of inducing permanent
changes in phenotype occur through genetic control of downstream genes. In this, androgens are the key
elements for the differentiation of male internal and external genitalia as well as other sexual organs and general
body composition, acting through a single androgen receptor. The androgen receptor is a nuclear transcription
factor modulating DNA transcription of respective target genes and thereby driving development and growth in a
stringent manner. The specificity of androgen action seems to be a strictly time-controlled process with the
androgen receptor acting in concert with different metabolites and an array of cofactors modulating the cellular
response and thereby permanently altering the phenotype of any given individual. For every cell programmed by
androgens, a specific ‘androgen response index’ must be proposed.
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Human sex development can be divided into three major
steps. First, the determination of the chromosomal set
with the presence or absence of a specific gene on the Y
chromosome termed SRY, as well as the sex differences
induced from the inequality of the sex chromosomes
and their corresponding genes [1,2]. Second, the devel-
opment of the gonad and its differentiation into either
testis or ovary [3,4]. Third, the control of the phenotype
of the individual by the secretion and action of specific
hormones, which in turn lead to additional genetic pro-
gramming. These steps have to occur in a stringent and
time-dependent manner to allow any individual to de-
velop into a male or a female. The sexual dimorphism is
then a major determinant for further development of the
individual and its capacity for reproduction, but also for
sex-related differences in health and disease. Examples
for this are differences in the occurrence of definedCorrespondence: olaf.hiort@uksh.de
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reproduction in any medium, provided the ordisorders, but also alterations in pharmacologic treat-
ment responses. This has been increasingly recognized,
but the role of sex-related endocrinology has been only
partly understood in its developmental aspects to date.
This review will describe the differential effects of andro-
gens in human sex development, focusing on recent
knowledge obtained from human natural models of dis-
tinct differences of sex development.Developmental aspects of sexual differentiation
Prenatal
Composition of the sexual phenotype is apparently
dependent on primary genetic events that stem from the
differences in genes on the X and Y chromosome as well
as their expression between males and females (2). How-
ever, the main aspects of gender development arise from
the endocrine induced differentiation of sexual organs
including the brain. Specific sex hormones present early
in development affect sexual differentiation in a perman-
ent and organizational manner.
The major hormones for differential male and female
sex development are mainly secreted from the testes [3].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the fifth week of gestation. The Sertoli cells secrete anti-
Mullerian hormone, a peptide responsible for the regres-
sion of the Mullerian ducts, thus inhibiting the forma-
tion of uterus and fallopian tubes in the male. From
around the sixth week of gestation, the Leydig cells
synthesize and secrete testosterone from cholesterol via
sequential actions of specific enzymes. Testosterone
reaches its target cells in a paracrine, but also in an
endocrine fashion through the blood. Within the target
cells, testosterone is metabolized, and the 5α-reduced
compound dihydrotestosterone (DHT) is required for
androgen-induced differentiation of the external geni-
talia. While testosterone stabilizes the Wolffian ducts to
develop into epididymis, vas deferens, and seminal
vesicle, DHT induces the formation of the prostate as
well as the differentiation of urogenital swellings, the
genital tubercle, and the urethral folds into penis and
scrotum [5].
In mammals, androgens act via a single androgen re-
ceptor (AR) in a very specific manner. Both sexes ex-
press the AR, but the usual lack of appropriate levels of
androgens in the female results in the development of
the genital tubercle into a clitoris, and the urogenital
swellings to become the labia majora [6]. In rodents,
the androgenization of the genitalia occurs in a
‘masculinization programming window’ between em-
bryonic days E15.5 and E17.5 [6,7]. If male mice are
treated with flutamide, a potent antiandrogen, during this
time interval, the morphology of the external genitalia will
be similar to female mice. In contrast, female mice will de-
velop male morphology if they are treated with testoster-
one propionate during this critical period [6].
In humans, the mechanisms explaining the effects of
androgens in genital development are well illustrated by
naturally occurring disorders of sex development (DSD)
[8]. A very interesting model to study the lack ofFigure 1 The prenatal development of the external genitalia. From an
genetically driven process, androgenization leads to formation of the phall
differentiated, time-controlled and dose-dependent androgen action as deandrogenic affects is complete androgen insensitivity
syndrome (CAIS). In 46,XY individuals, CAIS is caused
by deleterious mutations in the AR [9]. Individuals with
CAIS have normally developed testes secreting high
amounts of testosterone [10]. Their external phenotype
at birth is apparently completely female with a clitoris,
labia majora and female separation of vagina and urethra
[11]. An ‘opposite’ naturally occurring model is seen in
individuals with 46,XX karyotype and normally devel-
oped ovaries that have high amounts of androgens dur-
ing embryogenesis, for example, in congenital adrenal
hyperplasia (CAH) and adrenal androgen excess where
testosterone levels can reach the usual reference inter-
vals observed in males [12-15]. In such cases, the external
genitalia may be in some cases completely masculinized
with formation of a male size phallus with the urethral
opening at the tip of the glans, and the urogenital swellings
differentiated into a scrotum. We therefore propose a
highly androgen-dependent differentiation process leading
to either male (in the case of androgenization) or female
genitalia (lack of androgenization), which relies on ac-
tion strictly dependent on time, dose, and compound
(Figure 1).
Postnatal
Postnatally, both organizational (permanent) as well as
activational (temporary) effects of sex steroids are seen
on sexual organ function including brain structure and
behavior [16].
It seems clear that androgen action plays a major role
in body composition even in the neonate, as birth weight
highly correlates with androgenization status rather than
chromosomal sex [17]. The effects of embryonal
androgenization on specific parts of the body are not so
obvious and incompletely understood. In particular, the
study of biological effects on gender identity is challen-
ging for lack of experimental designs and ethical issues.initially undifferentiated appearance and after an initial primarily
us and scrotum, and to elongation of the urethra. This requires a
picted by the different arrows.
Hiort BMC Medicine 2013, 11:152 Page 3 of 7
http://www.biomedcentral.com/1741-7015/11/152Again, mainly the naturally occurring models (CAIS and
CAH) have been studied [16].
It has been well described that most individuals with
CAIS have a female gender identity. In contrast, 46,XX
individuals with CAH demonstrate behavioral traits as-
sociated with maleness, but their overall gender identity
is often female. In a study by Jurgensen et al. [18], chil-
dren with DSD were compared to controls with regard
to their gender role behavior. Child play activities were
attributed either as female and male and the choices of
the children documented and ranked. While 46,XY fe-
male children without any androgenization during em-
bryogenesis, namely complete loss of gonadal function
or CAIS, were choosing the same activities and interests
as 46,XX normal girls, partial androgenization lead to
more male behavioral traits. This seemed to be inde-
pendent from the actual status of androgens in these in-
dividuals, so that these experiments point towards a
programming of behavior at least partially due to
androgenization during embryogenesis [18].
Puberty is a time of very differentiated development
between the two sexes. The role of estrogens becomes
evident. Estrogens induce female, androgens male body
composition. In CAIS, at the time of puberty a
feminization is seen, despite the fact that these individ-
uals have very high androgen levels and their estrogen
levels are only in the upper male reference range [10].
This pubertal feminization in CAIS may be the result of
two effects, namely the lack of androgen action in con-
junction with an intracellular aromatization of testoster-
one to estrogens facilitating an uninhibited effect
through the estrogen receptor pathway [19]. If high
levels of androgens prevail in 46,XX probands with
CAH, androgenization might lead to elongation of the
clitoris, muscle growth occurs and also deepening of the
voice. Thus, the effects of androgens are again seen re-
gardless of genetic sex. Furthermore, the sex hormones
have quite different effects at the time of puberty com-
pared to their role during embryogenesis, as testosterone
itself is a major driver of male body composition with
respect to muscle build up and growth of the phallus,
but differentiating effects on the genitals are lost [9].
This obvious finding is demonstrated by the human
model with naturally occurring mutations in the 5α-
reductase 2 and therefore diminished DHT synthesis. 46,
XY children bearing defects of DHT synthesis may have
female appearing external genitalia at birth, but
masculinize due to unhampered testosterone synthesis
at the time of puberty [20]. This may actually lead to a
change of sex assignment and gender from female to
male in these individuals. It has to be assumed that the
gender identity in individuals with 5α-reductase 2 defi-
ciency may be variable and despite female appearance of
the genitalia at birth, a male gender identity may bepresent. This would constitute an obvious mismatch be-
tween androgenization status of the external genitalia at
birth and the possible androgen effects on gender iden-
tity. This point is crucial in the current debate on the
genetic and endocrine differences of ‘sex of brain’ with
regard to anatomy, behavior, and identity [21].
The biological explanation, why androgens exert such
time-dependent and differentiated effects on different
cells and tissues in the body through a single AR is still
not well understood. Postnatally, the evolutionary bio-
logical rationale would be to obtain growth and strength
to be fit for reproduction [22]. This includes the effects
of androgens on muscle strength, optimization of oxygen
saturation due to hemoglobin synthesis, fertility, but also
requirements for sexual attraction [23].
Differential androgen action
It seems clear that overall androgen levels play a major
role, but also different androgens may facilitate different
effects. Deslypere et al. [24] described different effects of
testosterone and DHT on the transcription of an artifi-
cial target gene in a cell-based assay. In the study by
Holterhus et al. [25], a similar system was utilized to
elucidate the differential effects of androgens and ana-
bolic steroids through the AR. They could demonstrate
that different hormones such as testosterone, DHT, as
well as weak androgens like dehydroepiandrosterone and
oxandrolone, and anabolics such as stanozolol and nan-
drolone, differ in their transduction of an AR-dependent
target gene, but that the results also depended on the
promoter system chosen in this artificial setting. From
these studies it can be concluded that within the cell,
different androgens influence expression of different tar-
get genes specifically [24,25].
Most likely, androgen-responsive cells can metabolize
steroid hormones in specific and time-dependent ways.
It was demonstrated that, for example, DHT synthesis
early in life is dependent on expression of 5α-reductase
type 2 in genital skin cells [26]. This expression pattern
may be altered in cells from individuals with androgen
insensitivity [27]. Later in life, 5α-reductase type 2 ex-
pression dwindles and its isoenzyme 5α-reductase type 1
is abundantly expressed [28] (Table 1). The effects on
the cellular androgen milieu are so far not elucidated,
but it can be perceived that the composition of andro-
genic metabolites can be quite variable, depending on
the expression pattern of steroidogenic enzymes within
the cell. In this regard it is of interest that different cell
types have different expression patterns of steroidogenic
enzymes that are also age dependent [29,30]. Further-
more, additional alternative pathways for androgen syn-
thesis may aggravate androgenic effects due to selective
expression patterns of isoenzymes or alternate enzymes.
One example of this is the ‘backdoor pathway’ of DHT
Table 1 Specific disorders of androgen biosynthesis and androgen action and the respective phenotypes
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through testosterone, utilizing instead 3α hydroxysteroid
dehydrogenase 3 with synthesis from androstanediol
[14,15]. Most likely this ‘backdoor’ pathway is one ex-
planation for the virilization of 46,XX girls with CAH
through excessive DHT formation in the external geni-
talia and it might play an important role in intrauterine
sex development.
Another example is the differential virilization of 46,
XY probands lacking testosterone synthesis due to defects
of 17β-hydroxysteroid dehydrogenase 3. These individuals
often have a female appearance at birth, but at the time of
puberty they depict measurable amounts of testosterone
and demonstrate a high degree of masculinization with
only slight feminization. Most likely, the pubertal testos-
terone synthesis from excessive amounts of androstene-
dione is due to postnatal expression of the isoenzyme
17β-hydroxysteroid dehydrogenase 5, which corresponds
to 3α hydroxysteroid dehydrogenase 2, in the Leydig cells
of the testes [31] (Table 1).Figure 2 The androgen specific cell differentiation is dependent on te
specificity of the androgen-androgen receptor (AR) complex in conce
GTF, general transcription factors; HRE, hormone response elements; HSP, hThe androgen-AR complex is dependent on a variety
of proteins involved in its shuttling towards the nucleus,
the unraveling and binding of the target DNA and also
in the transduction of the complex to activate or repress
target DNA transcription [32,33]. These mechanisms are
seemingly shared with other steroid hormone receptors,
as these receptors share the capability to bind to the
same hormone responsive elements on the target DNA
sequences. So there are common features of transcrip-
tional control of steroid hormone receptors, but also
specific androgen responsive elements that are only
bound by the AR [33]. After binding of the ligand, the
AR undergoes conformational changes and translocates
to the nucleus, where it homodimerizes in a ligand-
dependent manner. This is mediated by specific
sequences within the AR itself. The binding of
coregulators to regulate receptor-mediated transcription
control of target genes is a complex process. These
coregulators, acting as coactivators and corepressors, co-
ordinate the intercompartmental metabolic processesstosterone uptake, its intracellular metabolism and the
rt with coregulators in transcriptional control. CoR, coregulators;
eat shock proteins; P, phosphorylation sites.
Figure 3 A highly specific and time-dependent androgen response index for each cell must be proposed. This is an overall time-related
effect (T), which is seen in a specific time period (Tp) on n cells, where each cell responds according to specific androgens (androgen ×
androgenization factor) in relation to the androgen sensitivity as a ratio of the AR to its modulators evidenced by activation versus repression.
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forkhead box protein A1 (FOXA1), belonging to the
forkhead box transcription factors, the AR locates its
genomic target site. Other factors such as steroid recep-
tor coactivator-3 (SRC-3) induce the assembly of the ac-
tive coregulator-receptor complex [34]. For some
nuclear receptors, more than 300 distinct coregulators
are assumed modifying the receptor-mediated response.
If the coregulators act in concert, up to 2.5 × 1013 po-
tential distinct coregulator-receptor complexes might be
possible according to Lonard and O’Malley [35]. The dif-
ferential expression pattern of coregulators will be highly
cell specific and thereby lead to a cell-specific modifica-
tion pattern of androgen action [36] (Figure 2).
The ‘formula’ for cell-specific androgen programming
If transcriptional control of androgen-dependent target
cell responses is so distinct and well coordinated, the
genes that compose the overall androgenization of any
human should also demonstrate cell specificity. Again
the human model of androgen insensitivity has served in
elucidating some of these androgen-regulated genes.
Interestingly, there are apparently three major points to
be discussed, as follows. First, fetal sex development
leads to an androgen-controlled fixed program of gene
expression in the target cells. This ‘basal program’ is
expressed throughout life and corresponds to the overall
sex phenotype of a given person. Second, different cells
and tissues display their individual ‘androgen program’,
thereby depicting a topography of androgen-dependent
gene expression. Third, an acute response pattern to an-
drogens is seen with some genes in some cells.
Thus, in any individual, the responsiveness to andro-
gens will therefore be most likely be a product of all of
these factors, as proposed in an ‘androgen response
index’ seen in Figure 3.
This proposal has its foundation in the following ex-
periments again in cells derived from 46,XY controls and
cells derived from 46,XY females mostly with CAIS: Geni-
tal skin fibroblasts, which play a role in the differentiation
of the external genitalia and facilitate androgenization, are
almost ‘androgen insensitive’ postnatally [37]. Instead they
display a distinct and comprehensive expression pattern of
androgen-regulated genes even in patient-derived cells
that have long been androgen depleted. This fixed ‘andro-
gen-programmed’ expression pattern of genes is alsodifferent depending on the localization from which the tis-
sue was derived [38]. Overall, more than 600 genes were
differentially expressed between reference cells derived
from 46,XY males and proband cells from 46,XY CAIS fe-
males. In addition to the underlying fixed androgen-
programmed profile, some genes might be still be andro-
gen responsive in the cells. One example is apolipoprotein
D, which was significantly upregulated by DHT in scrotal
fibroblasts in the reference cells and showed no response
in the CAIS cells [39]. That in humans a cell-specific and
tissue-specific prenatal fixed androgen programming may
prevail was demonstrated by studying blood mononuclear
cells also from CAIS individuals and from male controls.
Again, a distinct set of transcripts was correlated with the
external genital appearance being male or female in 46,XY
individuals, however, the transcription profile differed ex-
tensively from that derived from genital skin fibroblasts
[40]. It has been hypothesized that epigenetic control
through the AR may contribute to sex hormone actions.
This has been evidenced by differences in HOXA5 methy-
lation in cells from 46,XY females with CAIS and controls
[41]. If the cellular effects of sex dimorphism are due to al-
tered epigenomic programming within the target cells has
to be investigated.
Conclusions
Sex and gender development in humans are tightly
controlled by genetic factors inducing organ, especially go-
nadal development and androgen-dependent program-
ming in a tissue-specific spatial and time-related fashion.
Modulation is facilitated through endocrine, paracrine,
and autocrine steroid synthesis, as well as through the re-
cruitment of many other regulators involved in the specifi-
city of androgen action through modification of the
hormone-receptor complex. This may be calculated as an
‘androgen sensitivity index’. Therapeutically, this may have
several implications: Prenatal effects of androgens or the
lack of androgenization cannot be reversed afterwards.
This is obvious seen in genital structures, but hypothetic-
ally also is implied for other tissues, namely also brain de-
velopment. Furthermore, any replacement of androgens
should take into account their differential effects in andro-
gen action and therefore supplementation of several com-
pounds may be useful to elicit specific effects. Third, the
timing of treatment with androgens is of importance for
their specific impact and side effects.
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